Compare Citius Pharmaceuticals Inc (CTXR) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs HSBC Holdings plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while HSBC Holdings plc trades at $99.61 (market cap $337.30B). The key difference: HSBC Holdings plc is far larger — about 23039.6× Citius Pharmaceuticals Inc's market cap, and HSBC Holdings plc pays a 3.78% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | HSBC | |
|---|---|---|
Market Cap | $14.64M | $337.30B |
Sector | Health | Technology |
52-Week High | $1.82 | $99.25 |
52-Week Low | $0.53 | $61.30 |
Enterprise Value | $10.86M | — |
Dividend Yield | — | 3.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
HSBC trades at $98.09, down 1.01% today but near its 52-week high of $99.47. Technical indicators show a bullish trend with strong moving average support. The bank reported $71.02B revenue and $22.29B net income for 2025, maintaining a robust 30.81% net margin. Recent news highlights strategic moves including AI partnerships with Google Cloud and potential divestitures of non-core units like its Turkey business.
HSBC presents a balanced investment case with steady profitability and strategic refocusing, but faces risks from global economic sensitivity and regulatory challenges. Analyst consensus is mixed with 38% buy ratings, suggesting cautious optimism amid execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
